Ally Bridge Group, a Chinese-based global healthcare-focused investment platform, has expanded its global pharmaceutical portfolio with several recent investments in therapeutics companies based in China, Europe and the US.
The Chinese investment firm said it plans to work closely with these companies by taking active board of directors and/or scientific advisory board positions. In the US, Ally Bridge Group completed investments in four companies including: V Biosciences (www.3vbio.com), is an oncology drug development company based inMenlo Park, California, targeting fatty acid synthase (FASN) in various solid…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
